デュポンの分析: ROE、ROA、純利益率の内訳
四半期データ
ROEを2つのコンポーネントに分解
Abbott Laboratories、 ROE の分解(四半期データ)
|
|
|
|
|
|
|
ROE |
= |
ROA |
× |
財務レバレッジ比率 |
2024/09/30 |
14.49% |
= |
7.76% |
× |
1.87 |
2024/06/30 |
14.13% |
= |
7.61% |
× |
1.86 |
2024/03/31 |
14.51% |
= |
7.77% |
× |
1.87 |
2023/12/31 |
14.83% |
= |
7.82% |
× |
1.90 |
2023/09/30 |
13.77% |
= |
7.16% |
× |
1.92 |
2023/06/30 |
13.88% |
= |
7.04% |
× |
1.97 |
2023/03/31 |
15.68% |
= |
7.87% |
× |
1.99 |
2022/12/31 |
18.90% |
= |
9.31% |
× |
2.03 |
2022/09/30 |
22.11% |
= |
10.84% |
× |
2.04 |
2022/06/30 |
23.44% |
= |
11.53% |
× |
2.03 |
2022/03/31 |
21.82% |
= |
10.44% |
× |
2.09 |
2021/12/31 |
19.75% |
= |
9.40% |
× |
2.10 |
2021/09/30 |
21.04% |
= |
9.82% |
× |
2.14 |
2021/06/30 |
18.86% |
= |
8.70% |
× |
2.17 |
2021/03/31 |
17.06% |
= |
7.86% |
× |
2.17 |
2020/12/31 |
13.71% |
= |
6.20% |
× |
2.21 |
2020/09/30 |
10.78% |
= |
4.90% |
× |
2.20 |
2020/06/30 |
10.17% |
= |
4.52% |
× |
2.25 |
2020/03/31 |
11.84% |
= |
5.36% |
× |
2.21 |
2019/12/31 |
11.86% |
= |
5.43% |
× |
2.18 |
2019/09/30 |
— |
= |
— |
× |
2.15 |
2019/06/30 |
— |
= |
— |
× |
2.16 |
2019/03/31 |
— |
= |
— |
× |
2.19 |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の株主資本利益率(ROE)が上昇した主な理由は、総資産利益率(ROA)で測定される収益性の向上です。
ROEを3つの要素に分解
Abbott Laboratories、 ROE の分解(四半期データ)
|
|
|
|
|
|
|
|
|
ROE |
= |
純利益率 |
× |
資産回転率 |
× |
財務レバレッジ比率 |
2024/09/30 |
14.49% |
= |
13.99% |
× |
0.55 |
× |
1.87 |
2024/06/30 |
14.13% |
= |
13.65% |
× |
0.56 |
× |
1.86 |
2024/03/31 |
14.51% |
= |
13.96% |
× |
0.56 |
× |
1.87 |
2023/12/31 |
14.83% |
= |
14.27% |
× |
0.55 |
× |
1.90 |
2023/09/30 |
13.77% |
= |
12.92% |
× |
0.55 |
× |
1.92 |
2023/06/30 |
13.88% |
= |
12.83% |
× |
0.55 |
× |
1.97 |
2023/03/31 |
15.68% |
= |
13.98% |
× |
0.56 |
× |
1.99 |
2022/12/31 |
18.90% |
= |
15.88% |
× |
0.59 |
× |
2.03 |
2022/09/30 |
22.11% |
= |
17.52% |
× |
0.62 |
× |
2.04 |
2022/06/30 |
23.44% |
= |
18.78% |
× |
0.61 |
× |
2.03 |
2022/03/31 |
21.82% |
= |
17.35% |
× |
0.60 |
× |
2.09 |
2021/12/31 |
19.75% |
= |
16.42% |
× |
0.57 |
× |
2.10 |
2021/09/30 |
21.04% |
= |
17.12% |
× |
0.57 |
× |
2.14 |
2021/06/30 |
18.86% |
= |
15.85% |
× |
0.55 |
× |
2.17 |
2021/03/31 |
17.06% |
= |
15.33% |
× |
0.51 |
× |
2.17 |
2020/12/31 |
13.71% |
= |
12.99% |
× |
0.48 |
× |
2.21 |
2020/09/30 |
10.78% |
= |
10.50% |
× |
0.47 |
× |
2.20 |
2020/06/30 |
10.17% |
= |
9.89% |
× |
0.46 |
× |
2.25 |
2020/03/31 |
11.84% |
= |
11.15% |
× |
0.48 |
× |
2.21 |
2019/12/31 |
11.86% |
= |
11.56% |
× |
0.47 |
× |
2.18 |
2019/09/30 |
— |
= |
— |
× |
— |
× |
2.15 |
2019/06/30 |
— |
= |
— |
× |
— |
× |
2.16 |
2019/03/31 |
— |
= |
— |
× |
— |
× |
2.19 |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の株主資本利益率(ROE)が増加した主な理由は、純利益率で測定した収益性の向上です。
ROEを5つの要素に分解
Abbott Laboratories、 ROE の分解(四半期データ)
|
|
|
|
|
|
|
|
|
|
|
|
|
ROE |
= |
税負担 |
× |
利息負担 |
× |
EBITマージン |
× |
資産回転率 |
× |
財務レバレッジ比率 |
2024/09/30 |
14.49% |
= |
0.85 |
× |
0.92 |
× |
17.86% |
× |
0.55 |
× |
1.87 |
2024/06/30 |
14.13% |
= |
0.85 |
× |
0.91 |
× |
17.47% |
× |
0.56 |
× |
1.86 |
2024/03/31 |
14.51% |
= |
0.86 |
× |
0.91 |
× |
17.76% |
× |
0.56 |
× |
1.87 |
2023/12/31 |
14.83% |
= |
0.86 |
× |
0.91 |
× |
18.20% |
× |
0.55 |
× |
1.90 |
2023/09/30 |
13.77% |
= |
0.83 |
× |
0.91 |
× |
17.07% |
× |
0.55 |
× |
1.92 |
2023/06/30 |
13.88% |
= |
0.82 |
× |
0.91 |
× |
17.11% |
× |
0.55 |
× |
1.97 |
2023/03/31 |
15.68% |
= |
0.83 |
× |
0.92 |
× |
18.24% |
× |
0.56 |
× |
1.99 |
2022/12/31 |
18.90% |
= |
0.83 |
× |
0.94 |
× |
20.31% |
× |
0.59 |
× |
2.03 |
2022/09/30 |
22.11% |
= |
0.85 |
× |
0.95 |
× |
21.87% |
× |
0.62 |
× |
2.04 |
2022/06/30 |
23.44% |
= |
0.85 |
× |
0.95 |
× |
23.22% |
× |
0.61 |
× |
2.03 |
2022/03/31 |
21.82% |
= |
0.85 |
× |
0.94 |
× |
21.51% |
× |
0.60 |
× |
2.09 |
2021/12/31 |
19.75% |
= |
0.86 |
× |
0.94 |
× |
20.30% |
× |
0.57 |
× |
2.10 |
2021/09/30 |
21.04% |
= |
0.88 |
× |
0.94 |
× |
20.83% |
× |
0.57 |
× |
2.14 |
2021/06/30 |
18.86% |
= |
0.89 |
× |
0.93 |
× |
19.25% |
× |
0.55 |
× |
2.17 |
2021/03/31 |
17.06% |
= |
0.90 |
× |
0.92 |
× |
18.54% |
× |
0.51 |
× |
2.17 |
2020/12/31 |
13.71% |
= |
0.90 |
× |
0.90 |
× |
16.00% |
× |
0.48 |
× |
2.21 |
2020/09/30 |
10.78% |
= |
0.88 |
× |
0.87 |
× |
13.70% |
× |
0.47 |
× |
2.20 |
2020/06/30 |
10.17% |
= |
0.88 |
× |
0.85 |
× |
13.12% |
× |
0.46 |
× |
2.25 |
2020/03/31 |
11.84% |
= |
0.87 |
× |
0.87 |
× |
14.76% |
× |
0.48 |
× |
2.21 |
2019/12/31 |
11.86% |
= |
0.90 |
× |
0.86 |
× |
14.88% |
× |
0.47 |
× |
2.18 |
2019/09/30 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
2.15 |
2019/06/30 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
2.16 |
2019/03/31 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
2.19 |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の株主資本利益率(ROE)が上昇した主な理由は、EBITマージン率で測定した営業利益率の増加です。
ROAを2つのコンポーネントに分解
Abbott Laboratories、 ROA の分解(四半期データ)
|
|
|
|
|
|
|
ROA |
= |
純利益率 |
× |
資産回転率 |
2024/09/30 |
7.76% |
= |
13.99% |
× |
0.55 |
2024/06/30 |
7.61% |
= |
13.65% |
× |
0.56 |
2024/03/31 |
7.77% |
= |
13.96% |
× |
0.56 |
2023/12/31 |
7.82% |
= |
14.27% |
× |
0.55 |
2023/09/30 |
7.16% |
= |
12.92% |
× |
0.55 |
2023/06/30 |
7.04% |
= |
12.83% |
× |
0.55 |
2023/03/31 |
7.87% |
= |
13.98% |
× |
0.56 |
2022/12/31 |
9.31% |
= |
15.88% |
× |
0.59 |
2022/09/30 |
10.84% |
= |
17.52% |
× |
0.62 |
2022/06/30 |
11.53% |
= |
18.78% |
× |
0.61 |
2022/03/31 |
10.44% |
= |
17.35% |
× |
0.60 |
2021/12/31 |
9.40% |
= |
16.42% |
× |
0.57 |
2021/09/30 |
9.82% |
= |
17.12% |
× |
0.57 |
2021/06/30 |
8.70% |
= |
15.85% |
× |
0.55 |
2021/03/31 |
7.86% |
= |
15.33% |
× |
0.51 |
2020/12/31 |
6.20% |
= |
12.99% |
× |
0.48 |
2020/09/30 |
4.90% |
= |
10.50% |
× |
0.47 |
2020/06/30 |
4.52% |
= |
9.89% |
× |
0.46 |
2020/03/31 |
5.36% |
= |
11.15% |
× |
0.48 |
2019/12/31 |
5.43% |
= |
11.56% |
× |
0.47 |
2019/09/30 |
— |
= |
— |
× |
— |
2019/06/30 |
— |
= |
— |
× |
— |
2019/03/31 |
— |
= |
— |
× |
— |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の総資産利益率(ROA)が上昇した主な理由は、純利益率で測定した収益性の向上です。
ROAを4つの要素に分解
Abbott Laboratories、 ROA の分解(四半期データ)
|
|
|
|
|
|
|
|
|
|
|
ROA |
= |
税負担 |
× |
利息負担 |
× |
EBITマージン |
× |
資産回転率 |
2024/09/30 |
7.76% |
= |
0.85 |
× |
0.92 |
× |
17.86% |
× |
0.55 |
2024/06/30 |
7.61% |
= |
0.85 |
× |
0.91 |
× |
17.47% |
× |
0.56 |
2024/03/31 |
7.77% |
= |
0.86 |
× |
0.91 |
× |
17.76% |
× |
0.56 |
2023/12/31 |
7.82% |
= |
0.86 |
× |
0.91 |
× |
18.20% |
× |
0.55 |
2023/09/30 |
7.16% |
= |
0.83 |
× |
0.91 |
× |
17.07% |
× |
0.55 |
2023/06/30 |
7.04% |
= |
0.82 |
× |
0.91 |
× |
17.11% |
× |
0.55 |
2023/03/31 |
7.87% |
= |
0.83 |
× |
0.92 |
× |
18.24% |
× |
0.56 |
2022/12/31 |
9.31% |
= |
0.83 |
× |
0.94 |
× |
20.31% |
× |
0.59 |
2022/09/30 |
10.84% |
= |
0.85 |
× |
0.95 |
× |
21.87% |
× |
0.62 |
2022/06/30 |
11.53% |
= |
0.85 |
× |
0.95 |
× |
23.22% |
× |
0.61 |
2022/03/31 |
10.44% |
= |
0.85 |
× |
0.94 |
× |
21.51% |
× |
0.60 |
2021/12/31 |
9.40% |
= |
0.86 |
× |
0.94 |
× |
20.30% |
× |
0.57 |
2021/09/30 |
9.82% |
= |
0.88 |
× |
0.94 |
× |
20.83% |
× |
0.57 |
2021/06/30 |
8.70% |
= |
0.89 |
× |
0.93 |
× |
19.25% |
× |
0.55 |
2021/03/31 |
7.86% |
= |
0.90 |
× |
0.92 |
× |
18.54% |
× |
0.51 |
2020/12/31 |
6.20% |
= |
0.90 |
× |
0.90 |
× |
16.00% |
× |
0.48 |
2020/09/30 |
4.90% |
= |
0.88 |
× |
0.87 |
× |
13.70% |
× |
0.47 |
2020/06/30 |
4.52% |
= |
0.88 |
× |
0.85 |
× |
13.12% |
× |
0.46 |
2020/03/31 |
5.36% |
= |
0.87 |
× |
0.87 |
× |
14.76% |
× |
0.48 |
2019/12/31 |
5.43% |
= |
0.90 |
× |
0.86 |
× |
14.88% |
× |
0.47 |
2019/09/30 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
2019/06/30 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
2019/03/31 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の総資産利益率(ROA)が上昇した主な理由は、EBITマージン率で測定した営業利益率の増加です。
当期純利益率の分解
Abbott Laboratories、純利益率の分解(四半期データ)
|
|
|
|
|
|
|
|
|
純利益率 |
= |
税負担 |
× |
利息負担 |
× |
EBITマージン |
2024/09/30 |
13.99% |
= |
0.85 |
× |
0.92 |
× |
17.86% |
2024/06/30 |
13.65% |
= |
0.85 |
× |
0.91 |
× |
17.47% |
2024/03/31 |
13.96% |
= |
0.86 |
× |
0.91 |
× |
17.76% |
2023/12/31 |
14.27% |
= |
0.86 |
× |
0.91 |
× |
18.20% |
2023/09/30 |
12.92% |
= |
0.83 |
× |
0.91 |
× |
17.07% |
2023/06/30 |
12.83% |
= |
0.82 |
× |
0.91 |
× |
17.11% |
2023/03/31 |
13.98% |
= |
0.83 |
× |
0.92 |
× |
18.24% |
2022/12/31 |
15.88% |
= |
0.83 |
× |
0.94 |
× |
20.31% |
2022/09/30 |
17.52% |
= |
0.85 |
× |
0.95 |
× |
21.87% |
2022/06/30 |
18.78% |
= |
0.85 |
× |
0.95 |
× |
23.22% |
2022/03/31 |
17.35% |
= |
0.85 |
× |
0.94 |
× |
21.51% |
2021/12/31 |
16.42% |
= |
0.86 |
× |
0.94 |
× |
20.30% |
2021/09/30 |
17.12% |
= |
0.88 |
× |
0.94 |
× |
20.83% |
2021/06/30 |
15.85% |
= |
0.89 |
× |
0.93 |
× |
19.25% |
2021/03/31 |
15.33% |
= |
0.90 |
× |
0.92 |
× |
18.54% |
2020/12/31 |
12.99% |
= |
0.90 |
× |
0.90 |
× |
16.00% |
2020/09/30 |
10.50% |
= |
0.88 |
× |
0.87 |
× |
13.70% |
2020/06/30 |
9.89% |
= |
0.88 |
× |
0.85 |
× |
13.12% |
2020/03/31 |
11.15% |
= |
0.87 |
× |
0.87 |
× |
14.76% |
2019/12/31 |
11.56% |
= |
0.90 |
× |
0.86 |
× |
14.88% |
2019/09/30 |
— |
= |
— |
× |
— |
× |
— |
2019/06/30 |
— |
= |
— |
× |
— |
× |
— |
2019/03/31 |
— |
= |
— |
× |
— |
× |
— |
レポートに基づく:
10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31), 10-K (報告日: 2019-12-31), 10-Q (報告日: 2019-09-30), 10-Q (報告日: 2019-06-30), 10-Q (報告日: 2019-03-31).
2024年第3 四半期の純利益率が上昇した主な理由は、EBITマージン率で測定した営業利益率の増加です。